0001209191-17-025569.txt : 20170405
0001209191-17-025569.hdr.sgml : 20170405
20170405160426
ACCESSION NUMBER: 0001209191-17-025569
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170403
FILED AS OF DATE: 20170405
DATE AS OF CHANGE: 20170405
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foundation Medicine, Inc.
CENTRAL INDEX KEY: 0001488613
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 271316416
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-418-2200
MAIL ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daly David
CENTRAL INDEX KEY: 0001320267
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36086
FILM NUMBER: 17742579
MAIL ADDRESS:
STREET 1: 33171 PASEO CERVEZA
CITY: SAN JUAN CAPISTRANO
STATE: CA
ZIP: 92675
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-04-03
0
0001488613
Foundation Medicine, Inc.
FMI
0001320267
Daly David
C/O FOUNDATION MEDICINE, INC.
150 SECOND STREET
CAMBRIDGE
MA
02141
0
1
0
0
Chief Commercial Officer
Common Stock
2017-04-03
4
S
0
2070
31.96
D
98582
D
Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.
The reporting person previously reported the restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale.
/s/ Robert W. Hesslein, as Attorney-in-Fact for David Daly
2017-04-05